

**CONTACT:** Karen A. Torres  
Cylex, Inc.  
410.964.0236, x140  
[ktorres@cylex.net](mailto:ktorres@cylex.net)

## **Cylex™ CEO Presides Over NASDAQ Closing Bell Ceremony**

### ***Prestigious Business Honor Based on National Fast Growth Recognition for Global Life Sciences Company***

**Columbia, MD USA, December 28, 2009** — Cylex CEO and President Brad L. Stewart presided over the NASDAQ closing bell ceremony on December 7, 2009. Cylex was honored as a Deloitte Technology Fast 500 winner in a special event hosted by the global financial services leader. Cylex was named one of the fastest growing businesses in North America in this year's Technology Fast 500 ranking public and private Technology, Media, Telecommunications, Life Sciences and Clean Technology companies. The ceremony took place at NASDAQ MarketSite in Times Square.

"We were very excited to play a part in the legendary NASDAQ Closing Bell ceremony, and we thank Deloitte for this special honor," said Brad Stewart. "After all of Cylex's success in 2009 and the continued industry acknowledgement of our business expansion and fast growth, it's very fitting that we finished out the year at the official center of the financial investment world."

The televised Closing Bell ceremony was broadcast live on financial cable channels and displayed on the seven-stories-tall MarketSite Tower that illuminates Times Square 24 hours a day.

In their first appearance on the prestigious Deloitte Fast Growth survey, Cylex was ranked the 4<sup>th</sup> fastest growing Life Sciences company in the Baltimore-Washington Metropolitan Area, which includes Central Maryland and Northern Virginia.

#### ***About Cylex, Inc.***

**Cylex** is a privately held global life science company that is the leader in the development and manufacture of *in vitro* diagnostic products. ImmuKnow®, the Company's first FDA cleared product, is sold in 18 countries and used to effectively manage and optimize immunosuppression in organ transplant patients. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD USA. For more information, visit [www.cylex.net](http://www.cylex.net).

#### ***About ImmuKnow***

**ImmuKnow** is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient. For more information, visit [www.cylex.net](http://www.cylex.net).

###